SAFETY AND EFFICACY OF SWITCHING TO TENOFOVIR ALAFENAMIDE (TAF) IN VIRALLY SUPPRESSED CHRONIC HEPATITIS B (CHB) PATIENTS WITH HEPATIC IMPAIRMENT: WEEK 24 RESULTS FROM A PHASE 2 OPEN-LABEL STUDY

被引：0
|
作者：
Coffin, Carla
Lim, Young-Suk
Bae, Ho
Heo, Jeong
Hui, Aric J.
Chen, Chien-Hung
Flaherty, John F.
Gaggar, Anuj
Mo, Shuyuan
Hahambis, Thomas A.
Jump, Belinda
Trinh, Huy N.
Tsang, Owen
Janssen, Harry L.
机构：
来源：
GASTROENTEROLOGY | 2020年 / 158卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Sa1525
引用
收藏
页码：S1320 / S1321
页数：2
相关论文
共 50 条
  • [31] One-year safety and efficacy of tenofovir alafenamide (TAF) in chronic hepatitis B (CHB): a HEllenic multicenter ReAl-life CLInical Study (HERACLIS TAF)
    Papatheodoridis, George
    Mimidis, Konstantinos
    Manolakopoulos, Spilios
    Gatselis, Nikolaos
    Goulis, Ioannis
    Andreas, Kapatais
    Manesis, Emmanouil
    Vasileiadis, Themistoklis
    Triantos, Christos
    Samonakis, Demetrious N.
    Sevastianos, Vasilis
    Karapatanis, Stylianos
    Elefsiniotis, Ioannis
    Deutsch, Melanie
    Mylopoulou, Theodora
    Papatheodoridi, Margarita
    Kranidioti, Hariklia
    Agorastou, Polyxeni
    Karaoulani, Theofanie
    Kyriazidou, Anastasia
    Zisimopoulos, Konstanitnos
    Dalekos, George
    JOURNAL OF HEPATOLOGY, 2021, 75 : S737 - S737
  • [32] A PHASE 3 STUDY OF TENOFOVIR ALAFENAMIDE COMPARED WITH TENOFOVIR DISOPROXIL FUMARATE IN PATIENTS WITH HBEAG-NEGATIVE, CHRONIC HEPATITIS B: WEEK 48 EFFICACY AND SAFETY RESULTS
    Buti, M.
    Gane, E.
    Seto, W. K.
    Chan, H. L. Y.
    Chuang, W. -L.
    Stepanova, T.
    Hui, A. J.
    Lim, Y. -S.
    Mehta, R.
    Janssen, H. L. A.
    Acharya, S. K.
    Flaherty, J. F.
    Massetto, B.
    Cathcart, A.
    Dinh, P.
    Subramanian, G. M.
    McHutchison, J. G.
    Pan, C.
    Brunetto, M.
    Izumi, N.
    Marcellin, P.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S135 - S136
  • [33] A phase 3 study comparing tenofovir alafenamide to tenofovir disoproxil fumarate in patients with HBeAg-negative, chronic hepatitis B: efficacy and safety results at week 96
    Brunetto, M.
    Lim, Y. S.
    Gane, E.
    Seto, W. K.
    Osipenko, M.
    Ahn, S. H.
    Janssen, H. L.
    Shukla, A.
    Chuang, W. L.
    Trinh, H.
    Celen, M. K.
    Flaherty, J. F.
    Lau, A. H.
    Gaggar, A.
    Suri, V.
    Bhardwaj, N.
    Kim, K.
    Subramanian, G. M.
    Pan, C.
    Izumi, N.
    Marcellin, P.
    Chan, H.
    Buti, M.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S25 - S26
  • [34] Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults aged>65 or older: week 48 results from a phase 3b, open-label trial
    Maggiolo, F.
    Rizzardini, G.
    Molina, J-M
    Pulido, F.
    De Wit, S.
    Vandekerckhove, L.
    Berenguer, J.
    D'Antoni, M.
    Blair, C.
    Chuck, S.
    Piontkowsky, D.
    Martin, H.
    McNicholl, I.
    Haubrich, R.
    Gallant, J.
    HIV MEDICINE, 2019, 20 : 138 - 138
  • [35] EFFECTIVENESS AND SAFETY OF SWITCHING TENOFOVIR DISOPROXIL FUMARATE AND ENTECAVIR TO TENOFOVIR ALAFENAMIDE FUMARATE ( TAF) IN VIROLOGICALLY SUPPRESSED CHRONIC HEPATITIS B VIRUSINFECTED PATIENTS WITH ONEMINUTE OSTEOPOROSIS RISK TEST
    Li, Hui
    Li, Chunmei
    Wei, Jia
    Liu, Yunhua
    Gong, Ming
    Zhang, Ruyi
    Geng, Jiawei
    Wang, Hongyan
    Yu, Zhijian
    Wang, Zi
    Liu, Xiang
    HEPATOLOGY, 2023, 78 : S513 - S513
  • [36] Improved Bone and Renal Safety at 1 Year after Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF): Results from 2 Phase 3 Studies in HBeAg-positive and HBeAg-negative Patients with Chronic Hepatitis B (CHB)
    Pan, Calvin Q.
    Brunetto, Maurizia R.
    Hui, Aric Josun
    Mehta, Rajiv
    Flaherty, John F.
    Suri, Vithika
    Wu, George
    Gaggar, Anuj
    Subramanian, Mani
    Nishiguchi, Shuhei
    Kim, Hyung J.
    Gane, Edward J.
    Chuang, Wan-Long
    HEPATOLOGY, 2017, 66 : 482A - 482A
  • [37] IMPROVED BONE AND RENAL SAFETY AT 1 YEAR AFTER SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) TO TENOFOVIR ALAFENAMIDE (TAF): RESULTS FROM 2 PHASE 3 STUDIES IN HBEAG-POSITIVE AND HBEAG-NEGATIVE PATIENTS WITH CHRONIC HEPATITIS B (CHB)
    Chan, Henry Lek-Yuen
    Pan, Calvin
    Brunetto, Maurizia
    Hui, Aric Josun
    Mehta, Rajiv
    Flaherty, John F.
    Suri, Vithika
    Wu, George
    Gaggar, Anuj
    Subramanian, G. Mani
    Nishiguchi, Shuhei
    Kim, Hyung Joon
    Gane, Edward
    Chuang, Wan Long
    GUT, 2018, 67 : A97 - A98
  • [38] TENOFOVIR ALAFENAMIDE (TAF) COMPARED WITH TENOFOVIR DISOPROXIL FUMARATE (TDF) IN PATIENTS WITH CHRONIC HBV: WEEK 96 EFFICACY AND SAFETY RESULTS IN CHINESE PATIENTS ENROLLED IN 2 GLOBAL PHASE 3 STUDIES
    Chan, Henry Lik-Yuen
    Seto, Wai Kay
    Fung, Scott
    Hou, Jinlin
    Pan, Calvin
    Chuang, Wan-Long
    Chang, Ting-Tsung
    Hui, Aric-Josun
    Chen, Chi-Yi
    Tsang, Tak Yin Owen
    Yang, Jenny
    Flaherty, John
    Gaggar, Anuj
    Mo, Shuyuan
    Kao, Jia-Horng
    GUT, 2018, 67 : A302 - A302
  • [39] Efficacy and Safety of Entecavir Versus Adefovir in Chronic Hepatitis B Patients With Hepatic Decompensation: A Randomized, Open-Label Study
    Liaw, Yun-Fan
    Raptopoulou-Gigi, Maria
    Cheinquer, Hugo
    Sarin, Shiv Kumar
    Tanwandee, Tawesak
    Leung, Nancy
    Peng, Cheng-Yuan
    Myers, Robert P.
    Brown, Robert S., Jr.
    Jeffers, Lennox
    Tsai, Naoky
    Bialkowska, Jolanta
    Tang, Shijie
    Beebe, Suzanne
    Cooney, Elizabeth
    HEPATOLOGY, 2011, 54 (01) : 91 - 100
  • [40] Efficacy and Safety of Tenofovir Disoproxil Orotate in Chronic Hepatitis B Patients Previously Treated with Tenofovir Disoproxil Fumarate: Multicenter, Open-Label, Prospective Study
    Chang, Young
    Kim, Sang-Gyune
    Jeong, Soung-Won
    Jang, Jae-Young
    Yoo, Jeong-Ju
    Lee, Sae-Hwan
    Kim, Young-Seok
    Kim, Hong-Soo
    Lee, Hyun-Woong
    Park, Suyeon
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (23)
12345